What is the rate of loss of response to infliximab therapy in Crohn's disease?
Chao
Jingdong
J
Mulani
Parvez
P
D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000188:drug therapy; D004361:Drug Tolerance; D006801:Humans; D000069285:Infliximab
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab